Hyperhomocysteinemia: An independent risk factor or a simple marker of vascular disease? 2. Epidemiological data;L'hperhomocystéinémie: Facteur de risque cardiovasculaire ou simple marqueur? 2. Données épidémiologiques

Pathologie Biologie

Volumn 51, Issue 2, 2003, Pages 111-121

  Guilland, J C ^a,d   Favier, A ^b   De Courcy, G Potier ^c   Galan, P ^c   Hercberg, S ^c  

^a Laboratoire de Physiologie   (France)

^b UFR de Pharmacie   (France)

^c INSERM   (France)

^d HÔPITAL DU BOCAGE   (France)

Author keywords

Cardiovascular disease; Homocysteine; Methylenetetrahydrofolate reductase; Stroke; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; PLACEBO; VITAMIN B GROUP; BIOLOGICAL MARKER; CYSTATHIONINE BETA SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MARKER; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; META ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; RISK FACTOR; VASCULAR DISEASE; AMINO ACID SUBSTITUTION; ARTERIOSCLEROSIS; BLOOD; CASE CONTROL STUDY; EPIDEMIOLOGY; EUROPE; GENETIC POLYMORPHISM; GENETICS; INTERVENTION STUDY; MISSENSE MUTATION; PROSPECTIVE STUDY; REVIEW; THROMBOPHILIA; UNITED STATES;

AMINO ACID SUBSTITUTION; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYSTATHIONINE BETA-SYNTHASE; EUROPE; HOMOCYSTINURIA; HUMANS; HYPERHOMOCYSTEINEMIA; INTERVENTION STUDIES; META-ANALYSIS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION, MISSENSE; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; UNITED STATES; VASCULAR DISEASES;

EID: 0041922337     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(03)00105-6     Document Type: Conference Paper

References (109)

1. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
2. Brattström L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
3. Cacciari E, Salardi S. Clinical and laboratory features of bomocystinuria. Haemostasis 1989;19(Suppl 1):10-3.
4. Medina M, Urdiales JL, Amores-Sanchez MI. Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem 2001;268:3871-82.
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
6. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
7. Evans RW, Shaten J, Hempel JD, Cutler JA. Kuller LH for the MRFIT Research Group Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
8. Folsom AR, Nieto J, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins. Circulation 1998;98:204-21.
9. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WL. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Arterioscler Thromb Vasc Biol 1998;140:3549-60.
10. Voutilainen S, Lakka TA, Hämelahti P, Lehtimäki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Studypdel. J Intern Med 2000;248:217-22.
11. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962;37:505-13.
12. Mudd SH, Finkelstein JD, Irrevere F, Laster L. Homocystinuria: an enzymatic defect. Science 1964;143:1443-5.
13. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
14. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
15. Hopkins I, Townley RR, Shipman RT. Cerebral thrombosis in a patient with homocystinuria. J Pediatr 1969;75:1082-3.
16. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997;20:295-300.
17. Yap S, Naughten E. Homocystinuria due to cystathionine betasynthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis 1998;21:738-47.
18. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect of thrombosus. N Engl J Med 1996;334:763-8.
19. Queré I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene. N Engl J Med 1996;335:289-90.
20. Kluitjmans LA, Boers GH, Verbruggen B, et al. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetatrahydrofolate reductase in the risk of venous thrombosis. Blood 1998;91:1015-8.
21. Yap S, O'Donnell KA, O'Neill C, et al. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency. Thromb Haemost 1999;81:502-5.
22. Malinow MR, Ducimetière P, Luc G, Evans AE, Arveiler D, Cambien F, et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
23. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997;349:397.
24. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976;57:1079-82.
25. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Glassman E, Gaull GE, et al. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985;6:725-6730.
26. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
27. Aranson DC, Onkenhout W, Raben AMTJ, Oudenhoven LFIJ, Brommer EJP, van Bockel JH. Impaired homocysteine metabolism: a risk factor in young adults with atherosclerotic arterial occlusive disease of the leg. Br J Surg 1994;81:1114-8.
28. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwalt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
29. Dudman NBP, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb 1993;13:1253-60.
30. Kang S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. J Clin Invest 1986;77:1482-6.
31. Israelsson B, Brattsröm LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-33.
32. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Umpson B. Homocyst(e)inemia in daily practice. Coron Artery Dis 1990;1:215-20.
33. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
34. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991;69:527-34.
35. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson D, Tishler PV, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992;268:877-81.
36. Pancharuniti N, Lewis CA, Sauberlich HE, Perekins LL, Go RC, Alvarez JO, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
37. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61.
38. Graham I. Interactions between homocysteinaemia and conventional risk factors in vascular disease. Eur Heart J 1994;15(Suppl):530 abstract.
39. Daly L, Graham I. Hyperhomocysteinaemia: a powerful risk factor for vascular disease. Presented at the Annual Scientific Meeting Working Group/Epidemiology and Prevention of the European Society of Cardiology; April 25, 1994; Venice, Italy. 1994.
40. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:460-4.
41. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-70.
42. Brattström LE, Harbebo JE, Hultberg BL. Moderate homocysteinemia. Stroke 1984;15:1012-6.
43. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T. Kita T Plasma sulfhydryl-containig amino acids in patients with cerebral infarction and in hypertensive patients. Atherosclerosis 1989;79:139-46.
44. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-6.
45. Brattström LE, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-21.
46. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-30.
47. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease - effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
48. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B. Olsson AG Hyperhomocyst(e)inemia: an independent risk factor for intermittent claudication. J Intern Med 1992;231:273-9.
49. Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM. Ueland PM Hyperhomocysteinemia in patients operated for lower extremity ischemia below the age 50: effect of smoking and extent of disease. Eur J Vasc Surg 1993;7:391-7.
50. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
51. Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Philippe F, Drobinski G, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronaryartery disease. Int J Cardiol 1997;60:295-300.
52. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-9.
53. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
54. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
55. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136-43.
56. Kark JD, Selhub J, Adler B, Gofin J, Abramson JH, Friedman G, et al. Nonfasting plasma total homocysteine level and mortality in middleaged and elderly men and women in Jerusalem. Ann Intern Med 1999;131:321-30.
57. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:891-900.
58. Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J. Rosenberg IH Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol 1999;19:2241-4.
59. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronaryartery disease. N Engl J Med 1997;337:230-6.
60. Taylor LM, Moneta GL, Sexton GJ, Schuff RA. Porter JM Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8-19.
61. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HU. Plasma homocysteine concentration predicts mortality in non-insulindependent diabetic patients with and without albuminuria. Kidney Int 1999;55:308-14.
62. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J. Rosenberg IH Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
63. Eichinger S, Stümpfen A, Hirschl M, Blalonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
64. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year followup. Arterioscler Thromb Vasc Biol 1998;18:1895-901.
65. Stubbs PJ, Al-Obaidi MK, Conroy R, Collinson P, Graham I, Noble MIM. Effects of plasma homocysteine concentration on early and late events in patients with acute coronarysyndromes. Circulation 2000;102:605-10.
66. Al-Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MIM. Elevated homocysteine levels are associated with increased myocardial injury in acute coronary syndromes. J Am Coll Cardiol 2000;36:1217-22.
67. Omland T, Samuelsson A, Hartford A, Herlitz J, Karlsson T, Christensen B, et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 2000;160:1834-40.
68. Benoit C, Furber A, Le Bouil A, Merheb M, Tadei A, Allain A, et al. Le dosage plasmatique de l'homocystéine n'est pas un facteur prédictif de resténose après angioplastie coronaire. Arch Mal Coeur 1999;1992:1457-60.
69. erson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
70. Hoogeveen EK, Kostense PJ, Jakobs C, Rauwerda JA, Dekker JM, Nijpels G, et al. Hyperhomocysteinemia is not associated with isolated crural arterial occlusive disease: The Hoorn Study. J Int Med 2000;247:442-8.
71. Bostom AG, Silberhatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-80.
72. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281:1817-21.
73. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
74. Whincup PH, Refsum H, Perry H, Morris R, Walker M, Lennon L, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999;82:448-54.
75. A'Brook R, Tavendale R, Tunstall-Pedoe H. Homocysteine and coronary risk in the general population: analysis from the Scottish Heart Study And Scottish MONICA surveys. Eur Heart J 1998;19(suppl.):8 (abstr).
76. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM. Shaper AG Prospective study of plasma homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
77. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000;86:1005-9.
78. Garg HC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, et al. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997;43:141-5.
79. Abdelmouttaleb I, Danchin N, Aimone-Gastin I, Namour F, Angioi M, Gelot MA, et al. Homocysteine, vitamins B6, B12, folate and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000;18:139-46.
80. Brattsröm L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.
81. Kluijtmans LAJ, Kastelein JIP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573-7.
82. Verhoef P, Rimm EB, Hunter DJ, Chen J, Willett WC, Kelsey K, et al. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S men. J Am Coll Cardiol 1998;32:353-9.
83. Brattsröm L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997;96:3805-7.
84. Tokgozoglu SL, Alikasifoglu M, Unsal, Atalar E, Aytemir K, Ozer N, et al. Methylenetetrahydrofolate reductase genotype and the risk and extent of coronary arterydisease in a population with low plasma folate. Heart 1999;81:518-22.
85. Gardemann A, Weidemann H, Philipp M, Katz N, Tillmans H, Hehrlein FW, et al. The TT genotype of the methylentetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at the high risk for coronary arterydisease. Eur Heart J 1999;20:584-92.
86. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999;93:2186-90.
87. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 2000;153:161-8.
88. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik P, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arteroscler Thromb Vasc Biol 1999;19:511-8.
89. Tosetto A, Rodighiero F, Martinelli I, DeStefano V, Missiaglia E. Chiusolo P et al Additional genetic risk factors for venous thrmoboembolism in carriers of the factor V Leiden mutation. Br J Haematol 1998;103:871-6.
90. Catttaneo M, Chantarrangkul V, Tailoi E, Santos JH, Tagliabue L. The G202110A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999;93:1-8.
91. Brown K, Luddington R, Baglin T. Effect of the MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998;103:42-4.
92. Demuth K, Moatti N, Hanon O, Benoit MO, Safar M. Gierd X Opposite effects of plasma homocysteine and methylene THF reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler Thromb Vasc Biol 1998;18:1838-43.
93. Candito M, Bedoucha P, Jambou D, Appert-Flory A, Fisher F, ParrotRoulaud F, et al. Accident vasculaire cérébral avec hyperhomocystéinémie. Arrêt des accidents thromboemboliques sous folates. Presse Méd 1997;26:1283-91.
94. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inemia. Lancet 1998;351:263 (letter).
95. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
96. van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwissen OJ. Banga JD Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinemia in patients with premature arterial disease and their relative. Atherosclerosis 1999;143:177-83.
97. de Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM. Rauwerda JA Normohomocysteinemia and vitamin-treated hyperhomocysteinemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease: A prospective cohort study. J Intern Med 1999;246:87-96.
98. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
99. Rees MM, Rodgers GM. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-9.
100. Mudd SH. Vascular disease and homocysteine metabolism. N Engl J Med 1985;313:751-3.
101. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Throm Res 1993;70:123-9.
102. Fermo I, Vignano d'Angelo S, Paroni R, Mazzola G, Calori G, d'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
103. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, Mukerjee D, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
104. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deepvein thrombosis. N Engl J Med 1996;334:759-62.
105. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3.
106. Admundsen T, Ueland PM. Waage A Plasma homocysteine levels in patients with deep veinous thrombosis. Arterioscler Thromb Vasc Biol 1995;15:1321-3.
107. Simioni P, Prandoni P, Burlina A, Tarmene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep-vein thrombosis. Thromb Haemost 1996;76:883-6.
108. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
109. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemost 1998;80:874-7.